Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARVINAS, INC.ARVN · Entity 5355 | Director | February 27, 2026 | March 03, 2026 |
| NextCure, Inc.NXTC · Entity 7461 | Director | June 18, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARVINAS, INC.
Report date February 27, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,122,183 |
Ending reported balance
After 2026-02-27 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-02-27 · Sale · Disposed 4,688 · Balance 1,152,792 F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-quarter of the reporting person's restricted stock units (RSUs) granted on February 22, 2023 when the reporting person was serving as President and CEO. The sale does not represent a discretionary trade. Row 2 · 2026-02-27 · Sale · Disposed 18,822 · Balance 1,133,970 F2: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on February 23, 2024 when the reporting person was serving as President and CEO. The sale does not represent a discretionary trade. Row 3 · 2026-02-27 · Sale · Disposed 11,787 · Balance 1,122,183 F3: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-quarter of the reporting person's restricted stock units (RSUs) granted on February 13, 2025 when the reporting person was serving as President and CEO. The sale does not represent a discretionary trade. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-quarter of the reporting person's restricted stock units (RSUs) granted on February 22, 2023 when the reporting person was serving as President and CEO. The sale does not represent a discretionary trade.
F2: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on February 23, 2024 when the reporting person was serving as President and CEO. The sale does not represent a discretionary trade.
F3: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-quarter of the reporting person's restricted stock units (RSUs) granted on February 13, 2025 when the reporting person was serving as President and CEO. The sale does not represent a discretionary trade.
NextCure, Inc.
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2036-06-17 | Direct | 2,340 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 2,340 · Balance 2,340 F1: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 22, 2026 20:14 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 2,340 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0000905148-26-003046 · form4.xml · derivative · entry 1 Houston John G · CIK 0001753537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,340 Underlying: Common Stock · 2,340 shares Expires 2036-06-17 F1 · derivative.exercise_date: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 01:57 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 11,787 | $13.14 | $154,881.18 |
DisclosureSEC source: 0001628280-26-013527 · wk-form4_1772503035.xml · nonDerivative · entry 3 Houston John G · CIK 0001753537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,122,183 F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-quarter of the reporting person's restricted stock units (RSUs) granted on February 13, 2025 when the reporting person was serving as President and CEO. The sale does not represent a discretionary trade. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 01:57 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 18,822 | $13.24 | $249,203.28 |
DisclosureSEC source: 0001628280-26-013527 · wk-form4_1772503035.xml · nonDerivative · entry 2 Houston John G · CIK 0001753537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,133,970 F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on February 23, 2024 when the reporting person was serving as President and CEO. The sale does not represent a discretionary trade. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 01:57 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 4,688 | $13.24 | $62,069.12 |
DisclosureSEC source: 0001628280-26-013527 · wk-form4_1772503035.xml · nonDerivative · entry 1 Houston John G · CIK 0001753537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,152,792 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-quarter of the reporting person's restricted stock units (RSUs) granted on February 22, 2023 when the reporting person was serving as President and CEO. The sale does not represent a discretionary trade. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 20:31 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 18,700 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0000905148-25-002246 · form4.xml · derivative · entry 1 Houston John G · CIK 0001753537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,700 Underlying: Common Stock · 18,700 shares Expires 2035-06-19 F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2026 and the date of the 2026 Annual Meeting of Stockholders. Read SEC document |
| February 24, 2025 Filed Feb 25, 2025 11:31 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 5,154 | $16.55 | $85,298.70 |
DisclosureSEC source: 0001655759-25-000048 · wk-form4_1740483094.xml · nonDerivative · entry 2 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,157,480 F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-quarter of the reporting person's RSUs granted on February 22, 2023. Read SEC document |
| February 24, 2025 Filed Feb 25, 2025 11:31 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 26,184 | $16.75 | $438,582.00 |
DisclosureSEC source: 0001655759-25-000048 · wk-form4_1740483094.xml · nonDerivative · entry 1 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,162,634 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on February 23, 2024. F2 · balance_after: Includes an aggregate of 137 shares of the issuer's common stock purchased under and in accordance with the issuer's 2018 Employee Stock Purchaser Plan in transactions exempt under Rule 16b-3. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 00:51 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 232,000 | $0.00 Strike: $17.67 | $0.00 |
DisclosureSEC source: 0001655759-25-000019 · wk-form4_1739926307.xml · derivative · entry 2 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,000 Underlying: Common Stock · 232,000 shares Expires 2035-02-12 F2 · derivative.exercise_date: The option was granted by the Issuer on February 13, 2025, pursuant to the Plan. The shares underlying the option vest over four years: 1/4 of the shares underlying the award will vest on February 13, 2026, with the remainder of the shares vesting in equal monthly installments following February 13, 2026 through February 13, 2029, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 00:51 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 152,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001655759-25-000019 · wk-form4_1739926307.xml · nonDerivative · entry 1 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,188,681 F1 · shares: The restricted stock units (each, an "RSU") were granted by the issuer on February 13, 2025, pursuant to its 2018 Stock Incentive Plan (the "Plan") and each RSU represents a contingent right to receive one share of the issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: 25% of the RSUs will vest on each of February 13, 2026, February 13, 2027, February 13, 2028 and February 13, 2029, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 21:04 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 18,700 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000905148-24-001766 · form4.xml · derivative · entry 1 Houston John G · CIK 0001753537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,700 Underlying: Common Stock · 18,700 shares Expires 2034-06-19 F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2025 and the date of the 2025 Annual Meeting of Stockholders. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 23:35 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 184,200 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001655759-24-000028 · wk-form4_1709076907.xml · derivative · entry 3 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,200 Underlying: Common Stock · 184,200 shares Expires 2034-02-22 F3 · derivative.exercise_date: The option was granted by the Issuer on February 23, 2024, pursuant to the Plan. The shares underlying the option will vest over two years: 1/2 of the shares underlying the award shall vest on February 23, 2025, with the remainder of the shares vesting on February 23, 2026. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 23:35 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 5,196 | $47.05 | $244,471.80 |
DisclosureSEC source: 0001655759-24-000028 · wk-form4_1709076907.xml · nonDerivative · entry 2 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,036,681 F2 · shares: This sale was made to cover withholding taxes following the vesting of previously granted Restricted Stock Units. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 23:35 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 124,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001655759-24-000028 · wk-form4_1709076907.xml · nonDerivative · entry 1 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,041,877 F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on February 23, 2024, pursuant to its 2018 Stock Incentive Plan (the "Plan") and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over two years: 1/2 of the shares underlying the award shall vest on February 23, 2025, with the remainder of the shares vesting on February 23, 2026. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 20:30 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001140361-23-031191 · form4.xml · derivative · entry 1 Houston John G · CIK 0001753537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2033-06-21 F1 · derivative.exercise_date: The option vests in full on the earlier of June 22, 2024 and the date of the 2024 Annual Meeting of Stockholders. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 02:50 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionRestricted Stock Units · Derivative | 17,510 | $0.00 | $0.00 |
DisclosureSEC source: 0001655759-23-000025 · wf-form4_167789819786057.xml · derivative · entry 3 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,510 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 70,042 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020. F4 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 70,042 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 02:50 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 5,878 | $29.53 | $173,577.34 |
DisclosureSEC source: 0001655759-23-000025 · wf-form4_167789819786057.xml · nonDerivative · entry 2 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 917,427 F2 · shares: This sale was made to cover withholding taxes following the vesting of previously granted Restricted Stock Units. F3 · price: The broker sold shares of the Issuer's common stock for certain employees following the vesting of previously granted Restricted Stock Units, including the common stock reported on this Form 4 by the reporting person, at a price of $29.53. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 02:50 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionCommon Stock | 17,510 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001655759-23-000025 · wf-form4_167789819786057.xml · nonDerivative · entry 1 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 923,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 21:57 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 186,250 | $0.00 Strike: $34.37 | $0.00 |
DisclosureSEC source: 0001655759-23-000018 · wf-form4_167727583617856.xml · derivative · entry 2 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,250 Underlying: Common Stock · 186,250 shares Expires 2033-02-21 F2 · derivative.exercise_date: The option was granted by the Issuer on February 22, 2023, pursuant to the Plan. The shares underlying the option will vest over four years: 1/4 of the shares underlying the award shall vest on February 22, 2024, with the remainder of the shares vesting in equal monthly installments following February 22, 2024 through February 23, 2027. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 21:57 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 61,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001655759-23-000018 · wf-form4_167727583617856.xml · nonDerivative · entry 1 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 905,795 F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on February 22, 2023, pursuant to its 2018 Stock Incentive Plan (the "Plan") and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: 1/4 of the shares underlying the award shall vest on February 22, 2024, with the remainder of the shares vesting in equal monthly installments following February 22, 2024 through February 23, 2027. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 21:30 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $4.77 | $0.00 |
DisclosureSEC source: 0001567619-22-013371 · doc1.xml · derivative · entry 1 Houston John G · CIK 0001753537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2032-06-22 F1 · derivative.exercise_date: The option vests in full on the earlier of June 23, 2023 and the date of the 2023 Annual Meeting of Stockholders. Read SEC document |
| March 04, 2022 Filed Mar 5, 2022 02:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionRestricted Stock Units · Derivative | 17,511 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016529 · doc4.xml · derivative · entry 4 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,510 Underlying: Common Stock · 17,511 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 70,042 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020. F5 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 70,042 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020. Read SEC document |
| March 04, 2022 Filed Mar 5, 2022 02:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 6,024 | $63.94 | $385,174.56 |
DisclosureSEC source: 0001209191-22-016529 · doc4.xml · nonDerivative · entry 2 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 843,820 F2 · shares: This sale was made to cover withholding taxes following the vesting of previously granted Restricted Stock Units. F3 · price: The broker sold shares of the Issuer's common stock for certain employees following the vesting of previously granted Restricted Stock Units, including the common stock reported on this Form 4 by the reporting person, at an average price of $63.94. Read SEC document |
| March 04, 2022 Filed Mar 5, 2022 02:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionCommon Stock | 17,511 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-016529 · doc4.xml · nonDerivative · entry 1 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 23, 2022 Filed Mar 5, 2022 02:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 200,500 | $0.00 Strike: $64.19 | $0.00 |
DisclosureSEC source: 0001209191-22-016529 · doc4.xml · derivative · entry 3 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,500 Underlying: Common Stock · 200,500 shares Expires 2032-02-22 F4 · derivative.exercise_date: This option award was granted on February 23, 2022. 1/4 of the shares underlying the award shall vest on February 23, 2023, with the remainder of the shares vesting in equal monthly installments following February 23, 2023 through February 23, 2026. Read SEC document |
| November 01, 2021 Filed Nov 4, 2021 01:46 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042947 · doc4.xml · derivative · entry 5 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2028-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F6 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of January 5, 2018, with the remainder of the shares vesting in equal monthly installments following January 5, 2018 through January 5, 2021. Read SEC document |
| November 01, 2021 Filed Nov 4, 2021 01:46 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 15,569 | $88.86 | $1,383,498.71 |
DisclosureSEC source: 0000899243-21-042947 · doc4.xml · nonDerivative · entry 4 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 832,333 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.4700 to $89.4500, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range within the range set forth in this footnote (5). Read SEC document |
| November 01, 2021 Filed Nov 4, 2021 01:46 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 15,918 | $87.98 | $1,400,478.37 |
DisclosureSEC source: 0000899243-21-042947 · doc4.xml · nonDerivative · entry 3 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847,902 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.4700 to $88.4600, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4). Read SEC document |
| November 01, 2021 Filed Nov 4, 2021 01:46 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 8,513 | $87.13 | $741,747.05 |
DisclosureSEC source: 0000899243-21-042947 · doc4.xml · nonDerivative · entry 2 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 863,820 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.4600 to $87.4500, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range within the range set forth in this footnote (3). Read SEC document |
| November 01, 2021 Filed Nov 4, 2021 01:46 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionCommon Stock | 40,000 | $16.00 | $640,000.00 |
DisclosureSEC source: 0000899243-21-042947 · doc4.xml · nonDerivative · entry 1 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 872,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 30, 2020. Read SEC document |
| September 02, 2021 Filed Sep 8, 2021 00:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionStock Option (right to buy) · Derivative | 2,462 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-21-055079 · doc4.xml · derivative · entry 4 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,272 Underlying: Common Stock · 2,462 shares Expires 2028-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested on March 31, 2019, with the remainder of the shares vesting in equal monthly installments following March 31, 2019 through March 31, 2022. Read SEC document |
| September 02, 2021 Filed Sep 8, 2021 00:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionStock Option (right to buy) · Derivative | 2,228 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-21-055079 · doc4.xml · derivative · entry 3 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 2,228 shares Expires 2028-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of January 5, 2018, with the remainder of the shares vesting in equal monthly installments following January 5, 2018 through January 5, 2021. Read SEC document |
| September 02, 2021 Filed Sep 8, 2021 00:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionCommon Stock | 2,462 | $16.00 | $39,392.00 |
DisclosureSEC source: 0001209191-21-055079 · doc4.xml · nonDerivative · entry 2 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 832,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2021 Filed Sep 8, 2021 00:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionCommon Stock | 2,228 | $16.00 | $35,648.00 |
DisclosureSEC source: 0001209191-21-055079 · doc4.xml · nonDerivative · entry 1 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 829,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2021 Filed Aug 5, 2021 00:05 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionStock Option (right to buy) · Derivative | 45,922 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-21-049804 · doc4.xml · derivative · entry 7 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,228 Underlying: Common Stock · 45,922 shares Expires 2028-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of January 5, 2018, with the remainder of the shares vesting in equal monthly installments following January 5, 2018 through January 5, 2021. Read SEC document |
| August 02, 2021 Filed Aug 5, 2021 00:05 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 2,746 | $100.66 | $276,412.36 |
DisclosureSEC source: 0001209191-21-049804 · doc4.xml · nonDerivative · entry 6 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827,643 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.450 to $100.92, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range within the range set forth in this footnote (7). Read SEC document |
| August 02, 2021 Filed Aug 5, 2021 00:05 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 3,441 | $99.96 | $343,962.36 |
DisclosureSEC source: 0001209191-21-049804 · doc4.xml · nonDerivative · entry 5 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830,389 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.45 to $100.375, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range within the range set forth in this footnote (6). Read SEC document |
| August 02, 2021 Filed Aug 5, 2021 00:05 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 7,600 | $98.86 | $751,336.00 |
DisclosureSEC source: 0001209191-21-049804 · doc4.xml · nonDerivative · entry 4 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 833,830 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.435 to $99.38, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range within the range set forth in this footnote (5). Read SEC document |
| August 02, 2021 Filed Aug 5, 2021 00:05 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 6,992 | $97.66 | $682,838.72 |
DisclosureSEC source: 0001209191-21-049804 · doc4.xml · nonDerivative · entry 3 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 841,430 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.39 to $97.97, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range within the range set forth in this footnote (4). Read SEC document |
| August 02, 2021 Filed Aug 5, 2021 00:05 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 25,143 | $96.96 | $2,437,865.28 |
DisclosureSEC source: 0001209191-21-049804 · doc4.xml · nonDerivative · entry 2 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848,422 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.39 to $97.35, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range within the range set forth in this footnote (3). Read SEC document |
| August 02, 2021 Filed Aug 5, 2021 00:05 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionCommon Stock | 45,922 | $16.00 | $734,752.00 |
DisclosureSEC source: 0001209191-21-049804 · doc4.xml · nonDerivative · entry 1 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 873,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 30, 2020. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 22:21 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $8.21 | $0.00 |
DisclosureSEC source: 0001567619-21-012672 · doc1.xml · derivative · entry 1 Houston John G · CIK 0001753537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2031-06-23 F1 · derivative.exercise_date: The option vests in full on the earlier of June 24, 2022 and the date of the 2022 Annual Meeting of Stockholders. Read SEC document |
| June 10, 2021 Filed Jun 12, 2021 00:07 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionStock Option (right to buy) · Derivative | 43,886 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-21-023375 · doc4.xml · derivative · entry 8 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,734 Underlying: Common Stock · 43,886 shares Expires 2028-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F7 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested on March 31, 2019, with the remainder of the shares vesting in equal monthly installments following March 31, 2019 through March 31, 2022. Read SEC document |
| June 10, 2021 Filed Jun 12, 2021 00:07 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 14,487 | $82.46 | $1,194,531.38 |
DisclosureSEC source: 0000899243-21-023375 · doc4.xml · nonDerivative · entry 6 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827,643 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F6 · price: The price reported in this Column 4 is a weighed average price. These shares were sold in multiple transactions at prices ranging from $82.0800 to $82.7600, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6). Read SEC document |
| June 10, 2021 Filed Jun 12, 2021 00:07 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 11,784 | $81.75 | $963,375.00 |
DisclosureSEC source: 0000899243-21-023375 · doc4.xml · nonDerivative · entry 5 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 842,130 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.0800 to $82.0750, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range within the range set forth in this footnote (5). Read SEC document |
| June 10, 2021 Filed Jun 12, 2021 00:07 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 17,615 | $80.52 | $1,418,356.28 |
DisclosureSEC source: 0000899243-21-023375 · doc4.xml · nonDerivative · entry 4 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 853,914 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.0000 to $80.9400, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4). Read SEC document |
| June 10, 2021 Filed Jun 12, 2021 00:07 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionCommon Stock | 43,886 | $16.00 | $702,176.00 |
DisclosureSEC source: 0000899243-21-023375 · doc4.xml · nonDerivative · entry 3 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 871,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 30, 2020. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:07 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionStock Option (right to buy) · Derivative | 700 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-21-023375 · doc4.xml · derivative · entry 7 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,620 Underlying: Common Stock · 700 shares Expires 2028-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F7 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested on March 31, 2019, with the remainder of the shares vesting in equal monthly installments following March 31, 2019 through March 31, 2022. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:07 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 700 | $80.15 | $56,103.53 |
DisclosureSEC source: 0000899243-21-023375 · doc4.xml · nonDerivative · entry 2 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827,643 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.0950 to $80.2150, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range within the range set forth in this footnote (3). Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:07 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionCommon Stock | 700 | $16.00 | $11,200.00 |
DisclosureSEC source: 0000899243-21-023375 · doc4.xml · nonDerivative · entry 1 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 828,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 30, 2020. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 02:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | Exercise / conversionRestricted Stock Units · Derivative | 17,510 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009196 · doc4.xml · derivative · entry 7 Houston John G · CIK 0001753537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,021 Underlying: Common Stock · 17,510 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. F9 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 70,042 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020. F9 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 70,042 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.